Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Neuroendocrine 5Neuroendocrine Tumors 3Lung Neoplasms 3Thyroid Carcinoma, Anaplastic 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Vulvar Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Gallbladder Neoplasms 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Bile Duct Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma, Mucinous 1Adenocarcinoma 1

Interventions

Trastuzumab 2Floxuridine 2tivozanib 1tipifarnib 1pembrolizumab 1entinostat 1atezolizumab 1Specimen Handling 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Nivolumab 1Molecular Diagnostic Techniques 1Melphalan 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunotherapy 1Fentanyl 1Drug Therapy 1Dexamethasone 1CTLA-4 Antigen 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × atezolizumab × Endocrine × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡